Birgitte Fagerlund
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Birgitte Fagerlund has a total of 213 co-authors. Here are the top co-authors by number of shared publications:
- Birte Yding Glenthoej
Center for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Center Glostrup, Glostrup, Copenhagen University Hospital - Mental Health Services CPH, Glostrup, Denmark
21 shared publications - Christos Pantelis
The University of Melbourne
11 shared publications - Bjørn Hylsebeck Ebdrup
Center for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Center Glostrup, Glostrup, Copenhagen University Hospital - Mental Health Services CPH, Glostrup, Denmark
10 shared publications - Cecilie Koldbæk Lemvigh
Center for Neuropsychiatric Schizophrenia Research and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Mental Health Centre Glostrup, Copenhagen University Hospital - Amager and Hvidovre, Denmark
8 shared publications - Egill Rostrup
Center for Neuropsychiatric Schizophrenia Research (CNSR) & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Center Glostrup, Copenhagen University Hospital – Mental Health Services CPH
8 shared publications - Merete Nordentoft
Danish Research Institute for Suicide Prevention, Mental Health Center Copenhagen
7 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e328
Anterograde and retrograde amnesia following electroconvulsive therapy: A controlled longitudinal study accounting for time and depression
Background: Electroconvulsive therapy (ECT) may be accompanied by amnesia. However, the extent to which different memory subtypes are affected is unclear, as well-controlled longitudinal studies are sparse. We aimed to investigate short- and long-term effects of ECT on different aspects of memory. Methods: We recruited patients with depression referred to ECT ( n = 31) or other treatment ( n = 21) and healthy participants ( n = 29). We measured autobiographical (Columbia Autobiographical Memory Interview – Short Form), verbal (Verbal Learning Test – Delayed), and visual (Rey Complex Figure Test) anterograde memory at baseline (T1), post-ECT (T2), and 6-month follow-up (T3). We performed a repeated measures mixed ANOVA for each outcome. An ANCOVA explored whether age and cognitive reserve were associated with severity of amnesia. ClinicalTrials.gov: NCT04160286. Results: A substantial effect of ECT on autobiographical memory was indicated by a group-by-time interaction, F (3.45, 103.51) = 22.261, p < 0.001, partial η 2 = 0.426. The effect remained stable, and inferior to control groups, at T3 ( p < 0.001). A large effect of ECT on verbal anterograde memory was suggested by a group-by-time interaction, F (2, 68) = 6.138, p = 0.004, partial η 2 = 0.153, reflecting transient impairment after ECT ( p = 0.009). No ECT-related decline in visual anterograde memory was observed ( p = 1.0). Neither age nor cognitive reserve was associated with degree of amnesia. Conclusions: Our findings suggest that ECT may be associated with autobiographical amnesia, potentially lasting at least 6 months, and transient verbal, but not visual, anterograde amnesia.
- 14 October 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e328
Open AccessAnterograde and retrograde amnesia following electroconvulsive therapy: A controlled longitudinal study accounting for time and depression
Background: Electroconvulsive therapy (ECT) may be accompanied by amnesia. However, the extent to which different memory subtypes are affected is unclear, as well-controlled longitudinal studies are sparse. We aimed to investigate short- and long-term effects of ECT on different aspects of memory. Methods: We recruited patients with depression referred to ECT ( n = 31) or other treatment ( n = 21) and healthy participants ( n = 29). We measured autobiographical (Columbia Autobiographical Memory Interview – Short Form), verbal (Verbal Learning Test – Delayed), and visual (Rey Complex Figure Test) anterograde memory at baseline (T1), post-ECT (T2), and 6-month follow-up (T3). We performed a repeated measures mixed ANOVA for each outcome. An ANCOVA explored whether age and cognitive reserve were associated with severity of amnesia. ClinicalTrials.gov: NCT04160286. Results: A substantial effect of ECT on autobiographical memory was indicated by a group-by-time interaction, F (3.45, 103.51) = 22.261, p < 0.001, partial η 2 = 0.426. The effect remained stable, and inferior to control groups, at T3 ( p < 0.001). A large effect of ECT on verbal anterograde memory was suggested by a group-by-time interaction, F (2, 68) = 6.138, p = 0.004, partial η 2 = 0.153, reflecting transient impairment after ECT ( p = 0.009). No ECT-related decline in visual anterograde memory was observed ( p = 1.0). Neither age nor cognitive reserve was associated with degree of amnesia. Conclusions: Our findings suggest that ECT may be associated with autobiographical amnesia, potentially lasting at least 6 months, and transient verbal, but not visual, anterograde amnesia.
- Open Access
- 18 July 2026
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 201, 601-607
Guided tapering of antipsychotics in patients with Schizophrenia: Relapse-status and cognition
- 18 July 2026
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 201, 601-607
Open AccessGuided tapering of antipsychotics in patients with Schizophrenia: Relapse-status and cognition
- Open Access
- 2 July 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Fish oil-derived fatty acids during pregnancy and risk of neurodevelopmental disorders in children at age 10 - A randomized controlled trial
Fish oil-derived omega-3 fatty acids (ꙍ-3 FA), particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are critical for early brain development, but evidence of causal effects from supplementation during pregnancy is limited. In the prospective COPSAC2010 cohort of 700 mother-child pairs, we investigated whether i) maternal DHA + EPA blood concentrations in mid-pregnancy and ii) fish oil supplementation in a randomized trial in late pregnancy influence neurodevelopmental outcomes at age 10. Maternal blood DHA + EPA concentrations were measured at 24 weeks gestation, followed by randomization to 2.4 g daily fish oil (37% DHA, 55% EPA) or placebo until one-week postpartum. Psychopathology was assessed in the children at age 10 using the Kiddie Schedule for Affective Disorders and Schizophrenia -Present and Lifetime version and parental-rated questionnaires Statistical analyses included logistic and linear regression models. Higher maternal DHA + EPA concentrations were associated with reduced ADHD risk (OR 0.71, p = 0.03) and ADHD symptom load (β = -1.14, p < 0.001) in unadjusted analyses but not after confounder adjustment (OR 0.82, p = 0.24; β = -0.49, p = 0.21). Similar trends were observed for autistic traits (β = -1.96, [-1.11; -0.24] p = 0.01), but not significant after confounder adjustment. Fish oil supplementation showed no significant reduction in ADHD (OR 0.79, p = 0.37) or ASD risk (OR 0.56, p = 0.42). A secondary analysis suggested a protective effect for ADHD Predominantly Inattentive Presentation, although it did not hold significance after correction for multiple testing (OR 0.41; p = 0.03; FDRp=0.12). Thus, potential effects on inattentive ADHD symptoms should be explored in future studies.
- 2 July 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Open AccessFish oil-derived fatty acids during pregnancy and risk of neurodevelopmental disorders in children at age 10 - A randomized controlled trial
Fish oil-derived omega-3 fatty acids (ꙍ-3 FA), particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are critical for early brain development, but evidence of causal effects from supplementation during pregnancy is limited. In the prospective COPSAC2010 cohort of 700 mother-child pairs, we investigated whether i) maternal DHA + EPA blood concentrations in mid-pregnancy and ii) fish oil supplementation in a randomized trial in late pregnancy influence neurodevelopmental outcomes at age 10. Maternal blood DHA + EPA concentrations were measured at 24 weeks gestation, followed by randomization to 2.4 g daily fish oil (37% DHA, 55% EPA) or placebo until one-week postpartum. Psychopathology was assessed in the children at age 10 using the Kiddie Schedule for Affective Disorders and Schizophrenia -Present and Lifetime version and parental-rated questionnaires Statistical analyses included logistic and linear regression models. Higher maternal DHA + EPA concentrations were associated with reduced ADHD risk (OR 0.71, p = 0.03) and ADHD symptom load (β = -1.14, p < 0.001) in unadjusted analyses but not after confounder adjustment (OR 0.82, p = 0.24; β = -0.49, p = 0.21). Similar trends were observed for autistic traits (β = -1.96, [-1.11; -0.24] p = 0.01), but not significant after confounder adjustment. Fish oil supplementation showed no significant reduction in ADHD (OR 0.79, p = 0.37) or ASD risk (OR 0.56, p = 0.42). A secondary analysis suggested a protective effect for ADHD Predominantly Inattentive Presentation, although it did not hold significance after correction for multiple testing (OR 0.41; p = 0.03; FDRp=0.12). Thus, potential effects on inattentive ADHD symptoms should be explored in future studies.
- Open Access
Associations between Multiple Early Risk Factors and Cognitive Functioning at Time of Diagnosis in Children, Adolescents, and Adults with First-Episode Psychosis
Background: Schizophrenia is associated with widespread cognitive impairments. Several early risk factors for schizophrenia have been identified, and some studies suggest associations between these early risk factors and cognition, yet the literature is sparse in psychosis. Methods: Clinical cohorts of child/adolescent and adult patients with first-episode psychosis (FEP) and healthy controls (HC) were linked with register-based information (N=276). Gestational age, Apgar scores, birth weight and length, parental age, and season of birth were extracted from the Danish medical birth registry. Cognition was assessed at time of diagnosis using BACS, CANTAB, and WAIS-III/WISC-IV. Missing data was imputed using MICE. Canonical correlation analysis (CCA) was used to examine patterns of associations. Post hoc analyses explored group differences according to diagnosis, age, and sex. Results: CCA resulted in two significant patterns of associations. CCA1 was stable across imputations (r=0.44, p =.036, p min = .017, p max = .055), and constituted by a risk profile of lower maternal age, lower birth length, being small for gestational age, and lower birth weight and a cognitive profile of lower estimated IQ and poorer working memory, mental flexibility, processing speed, verbal fluency, and motor latency. The pattern was more expressed in FEP compared to HC and in adults compared to children. CCA2 was more unstable across imputations (r=0.38, p =.033, p min =.003, p max =.168) and constituted by a broad pattern of minor loadings. Conclusion: Cognitive functioning later in life is associated with multiple early risk factors, underscoring the complexity of developmental processes and the importance of the early developmental context in shaping cognitive trajectories.
Open AccessAssociations between Multiple Early Risk Factors and Cognitive Functioning at Time of Diagnosis in Children, Adolescents, and Adults with First-Episode Psychosis
Background: Schizophrenia is associated with widespread cognitive impairments. Several early risk factors for schizophrenia have been identified, and some studies suggest associations between these early risk factors and cognition, yet the literature is sparse in psychosis. Methods: Clinical cohorts of child/adolescent and adult patients with first-episode psychosis (FEP) and healthy controls (HC) were linked with register-based information (N=276). Gestational age, Apgar scores, birth weight and length, parental age, and season of birth were extracted from the Danish medical birth registry. Cognition was assessed at time of diagnosis using BACS, CANTAB, and WAIS-III/WISC-IV. Missing data was imputed using MICE. Canonical correlation analysis (CCA) was used to examine patterns of associations. Post hoc analyses explored group differences according to diagnosis, age, and sex. Results: CCA resulted in two significant patterns of associations. CCA1 was stable across imputations (r=0.44, p =.036, p min = .017, p max = .055), and constituted by a risk profile of lower maternal age, lower birth length, being small for gestational age, and lower birth weight and a cognitive profile of lower estimated IQ and poorer working memory, mental flexibility, processing speed, verbal fluency, and motor latency. The pattern was more expressed in FEP compared to HC and in adults compared to children. CCA2 was more unstable across imputations (r=0.38, p =.033, p min =.003, p max =.168) and constituted by a broad pattern of minor loadings. Conclusion: Cognitive functioning later in life is associated with multiple early risk factors, underscoring the complexity of developmental processes and the importance of the early developmental context in shaping cognitive trajectories.
- Open Access
- 5 May 2026
- Published by Springer Nature in Research Square
Individual Profiling Across the Psychosis Continuum using Affinity Scores
Patients with psychotic disorders exhibit a continuum of heterogenous symptoms with both differences and similarities across diagnostic categories and illness stages. Tools that capture this individualized variability are warranted for tailoring personalized treatment. To address this, we employed Affinity Scores as an individual-centric statistical approach that complements diagnostic information by modeling individualized patterns within multivariate data. We included 670 participants aged 18–60: 284 healthy controls [HC], 201 individuals at ultra-high risk [UHR], 128 patients with first-episode psychosis [FEP], and 57 patients with a history of schizophrenia [SCZ]. Clinical, cognitive, and demographic data were standardized, and dimensional Affinity Scores were computed using participant-specific neighborhood graphs, weighting proximal neighbors. Multivariate features were derived by integrating Affinity Scores across domains. We evaluated classification accuracy of diagnostic alignment, tested associations with regional brain volumes, and applied elastic net logistic regression to predict UHR-outcomes after one year (remission and transition to psychosis). Affinity Scores revealed diverse individual profiles across the psychosis continuum. Diagnostic classification accuracies ranged from 0.59–0.85, improving with contextual neighborhood information. Significant associations emerged between Affinity Scores and frontal, temporal, and parietal brain volumes, reflecting both shared and distinct neurobiological patterns. For UHR-individuals, two heterogeneity indices predicted transition (ROC AUC = 0.865, Brier = 0.027) and remission (ROC AUC = 0.813, Brier = 0.045) after one year, indicating increased diversity as prognostically relevant. This proof-of-concept study demonstrates how Affinity Scores capture individual-level heterogeneity, complement diagnostic information and predict clinical outcome, and holds promise as a novel and transparent tool for improved diagnostics and tailored treatment strategies informed by individualized profiles.
- 5 May 2026
- Published by Springer Nature in Research Square
Open AccessIndividual Profiling Across the Psychosis Continuum using Affinity Scores
Patients with psychotic disorders exhibit a continuum of heterogenous symptoms with both differences and similarities across diagnostic categories and illness stages. Tools that capture this individualized variability are warranted for tailoring personalized treatment. To address this, we employed Affinity Scores as an individual-centric statistical approach that complements diagnostic information by modeling individualized patterns within multivariate data. We included 670 participants aged 18–60: 284 healthy controls [HC], 201 individuals at ultra-high risk [UHR], 128 patients with first-episode psychosis [FEP], and 57 patients with a history of schizophrenia [SCZ]. Clinical, cognitive, and demographic data were standardized, and dimensional Affinity Scores were computed using participant-specific neighborhood graphs, weighting proximal neighbors. Multivariate features were derived by integrating Affinity Scores across domains. We evaluated classification accuracy of diagnostic alignment, tested associations with regional brain volumes, and applied elastic net logistic regression to predict UHR-outcomes after one year (remission and transition to psychosis). Affinity Scores revealed diverse individual profiles across the psychosis continuum. Diagnostic classification accuracies ranged from 0.59–0.85, improving with contextual neighborhood information. Significant associations emerged between Affinity Scores and frontal, temporal, and parietal brain volumes, reflecting both shared and distinct neurobiological patterns. For UHR-individuals, two heterogeneity indices predicted transition (ROC AUC = 0.865, Brier = 0.027) and remission (ROC AUC = 0.813, Brier = 0.045) after one year, indicating increased diversity as prognostically relevant. This proof-of-concept study demonstrates how Affinity Scores capture individual-level heterogeneity, complement diagnostic information and predict clinical outcome, and holds promise as a novel and transparent tool for improved diagnostics and tailored treatment strategies informed by individualized profiles.
- Open Access
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 2846-2857
Tadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial
BACKGROUND: White matter hyperintensities and reduced cerebral blood flow are hallmarks of cerebral small vessel disease (CSVD). We tested the feasibility of daily treatment with the vasoactive drug tadalafil in patients with CSVD and its effects on cognition and imaging markers of CSVD. METHODS: The ETLAS-2 trial (Effect of Tadalafil in Lacunar Stroke) was a randomized, placebo-controlled, double-blind, parallel phase II trial testing 3 months of daily tadalafil 20 mg versus placebo in patients with CSVD and previous stroke or transient ischemic attack. Participants were included from the Capital Region of Denmark from 2022 to 2024. Outcomes were assessed at baseline and after 3 months. A binary logistic regression model with the treatment group as a covariate was used to calculate the primary outcome of feasibility (≥90% study drug compliance). Secondary outcomes included the Montreal Cognitive Assessment, magnetic resonance imaging markers of CSVD (Standards for Reporting Vascular Changes on Neuroimaging criteria), blood pressure, and adverse events. RESULTS: We included 76 participants (20 female, mean age, 68.0±8.9 years). Seventy-one initiated treatment, and 26 of 38 participants with tadalafil were ≥90% compliant versus 31 of 33 with placebo (odds ratio, 0.13 [95% CI, 0.03–0.69]; P =0.030). There was a female preponderance in tadalafil dropouts, with 46% of females stopping treatment, compared with only 16% of males. Adverse events occurred in 76% of participants with tadalafil versus 36% with placebo (odds ratio, 5.49 [95% CI, 1.81–18.07]; P =0.001). A trend toward lower white matter hyperintensity volume at follow-up was observed in the tadalafil group in the unadjusted per-protocol analysis (relative change, 0.939 [95% CI, 0.881–1.001]; P =0.054). No differences were observed in cognition, mental well-being, or blood pressure. CONCLUSIONS: In participants with CSVD, adherence to tadalafil was significantly lower than to placebo and did not meet the prespecified compliance threshold. We observed a nonsignificant reduction in white matter hyperintensity volume after tadalafil, which warrants larger and prolonged studies with reduced tadalafil doses to explore potential benefits in CSVD. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05173896.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 2846-2857
Open AccessTadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial
BACKGROUND: White matter hyperintensities and reduced cerebral blood flow are hallmarks of cerebral small vessel disease (CSVD). We tested the feasibility of daily treatment with the vasoactive drug tadalafil in patients with CSVD and its effects on cognition and imaging markers of CSVD. METHODS: The ETLAS-2 trial (Effect of Tadalafil in Lacunar Stroke) was a randomized, placebo-controlled, double-blind, parallel phase II trial testing 3 months of daily tadalafil 20 mg versus placebo in patients with CSVD and previous stroke or transient ischemic attack. Participants were included from the Capital Region of Denmark from 2022 to 2024. Outcomes were assessed at baseline and after 3 months. A binary logistic regression model with the treatment group as a covariate was used to calculate the primary outcome of feasibility (≥90% study drug compliance). Secondary outcomes included the Montreal Cognitive Assessment, magnetic resonance imaging markers of CSVD (Standards for Reporting Vascular Changes on Neuroimaging criteria), blood pressure, and adverse events. RESULTS: We included 76 participants (20 female, mean age, 68.0±8.9 years). Seventy-one initiated treatment, and 26 of 38 participants with tadalafil were ≥90% compliant versus 31 of 33 with placebo (odds ratio, 0.13 [95% CI, 0.03–0.69]; P =0.030). There was a female preponderance in tadalafil dropouts, with 46% of females stopping treatment, compared with only 16% of males. Adverse events occurred in 76% of participants with tadalafil versus 36% with placebo (odds ratio, 5.49 [95% CI, 1.81–18.07]; P =0.001). A trend toward lower white matter hyperintensity volume at follow-up was observed in the tadalafil group in the unadjusted per-protocol analysis (relative change, 0.939 [95% CI, 0.881–1.001]; P =0.054). No differences were observed in cognition, mental well-being, or blood pressure. CONCLUSIONS: In participants with CSVD, adherence to tadalafil was significantly lower than to placebo and did not meet the prespecified compliance threshold. We observed a nonsignificant reduction in white matter hyperintensity volume after tadalafil, which warrants larger and prolonged studies with reduced tadalafil doses to explore potential benefits in CSVD. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05173896.
- Open Access
- 1 July 2025
- Published by Springer Nature in Research Square
Paediatric Autism Communication Therapy (PACT) versus management as usual in autistic Children: A protocol for a Danish pragmatic, national, randomised clinical trial: DAN-PACT
Background Despite autism being a lifelong developmental condition affecting approximately 2% of children and young people worldwide, interventions aimed at improving core autism features are sparse. Paediatric Autism Communication Therapy (PACT) is among the first parent-mediated developmental interventions, provided in naturalistic settings, to show promising results in core feature improvement. Methods DAN-PACT is an investigator-initiated, independently funded, multi-centre, parallel group superiority, randomised clinical trial, which aims to assess benefits and harms of PACT in 2.0-6.9 year-old children with a recent autism diagnosis, comparing PACT combined with management as usual to management as usual alone. 280 autistic children from all regions of Denmark will be included. Primary outcome assessors, data managers, statisticians and conclusion drawers will be blinded. The primary outcome is magnitude of autism features as measured by the ADOS-2 CSS. The sample size calculation is based on a minimal important difference of 0.66 points, corresponding to a 2-3 point difference in ADOS raw scores. Secondary outcomes are changes in child social communication skills measured with the BOSCC, child adaptive skills measured with the VABS-3, and parents’ assessment of their own and their child’s quality of life. Several exploratory outcomes will be assessed, including adverse events during the trial period. Trial staff will be trained to perform both PACT and enhanced management as usual, assessing manual fidelity of PACT and measuring a broad range of benefits and harms with repeated measures. Discussion DAN-PACT aims to minimize risks of bias, anchor the trial in a naturalistic clinical setting, and extend the scope of outcome measures used in previous PACT studies, achieved by blinding raters to all observational outcomes, including a large sample of young autistic children, and using an enhanced management as usual control sample. Trial limitations are the risk of missing data and the inability to blind parent participants to their group allocation and their rating of several secondary and exploratory outcomes. In addition, there is no consensus on the magnitude of the minimal important difference on ADOS-CSS or BOSCC, which are therefore estimated pragmatically. Trial registration: Registered Dec. 22, 2022 at clinicaltrials.gov, identifier: NCT05673096 Keywords: autism, parent-mediated intervention, young children, randomised clinical trial
- 1 July 2025
- Published by Springer Nature in Research Square
Open AccessPaediatric Autism Communication Therapy (PACT) versus management as usual in autistic Children: A protocol for a Danish pragmatic, national, randomised clinical trial: DAN-PACT
Background Despite autism being a lifelong developmental condition affecting approximately 2% of children and young people worldwide, interventions aimed at improving core autism features are sparse. Paediatric Autism Communication Therapy (PACT) is among the first parent-mediated developmental interventions, provided in naturalistic settings, to show promising results in core feature improvement. Methods DAN-PACT is an investigator-initiated, independently funded, multi-centre, parallel group superiority, randomised clinical trial, which aims to assess benefits and harms of PACT in 2.0-6.9 year-old children with a recent autism diagnosis, comparing PACT combined with management as usual to management as usual alone. 280 autistic children from all regions of Denmark will be included. Primary outcome assessors, data managers, statisticians and conclusion drawers will be blinded. The primary outcome is magnitude of autism features as measured by the ADOS-2 CSS. The sample size calculation is based on a minimal important difference of 0.66 points, corresponding to a 2-3 point difference in ADOS raw scores. Secondary outcomes are changes in child social communication skills measured with the BOSCC, child adaptive skills measured with the VABS-3, and parents’ assessment of their own and their child’s quality of life. Several exploratory outcomes will be assessed, including adverse events during the trial period. Trial staff will be trained to perform both PACT and enhanced management as usual, assessing manual fidelity of PACT and measuring a broad range of benefits and harms with repeated measures. Discussion DAN-PACT aims to minimize risks of bias, anchor the trial in a naturalistic clinical setting, and extend the scope of outcome measures used in previous PACT studies, achieved by blinding raters to all observational outcomes, including a large sample of young autistic children, and using an enhanced management as usual control sample. Trial limitations are the risk of missing data and the inability to blind parent participants to their group allocation and their rating of several secondary and exploratory outcomes. In addition, there is no consensus on the magnitude of the minimal important difference on ADOS-CSS or BOSCC, which are therefore estimated pragmatically. Trial registration: Registered Dec. 22, 2022 at clinicaltrials.gov, identifier: NCT05673096 Keywords: autism, parent-mediated intervention, young children, randomised clinical trial
- Open Access
- 10 April 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (4) , e1004454
Maternal dietary patterns, breastfeeding duration, and their association with child cognitive function and head circumference growth: A prospective mother–child cohort study
Background: Early life is a critical period for neurodevelopment, where factors such as maternal nutrition and breastfeeding duration significantly impact the growth of head circumference and cognitive development in children. Our study aimed to explore the associations between maternal dietary patterns during pregnancy, duration of breastfeeding, and their impacts on child head circumference and cognitive outcomes. Methods and findings: Our study utilised data from the Copenhagen Prospective Studies on Asthma in Childhood 2010 cohort, which enrolled 700 mother–child pairs between 2008 and 2010 with 86% clinical follow-up at age 10. Pregnancy dietary patterns, described as ‘Varied’ and ‘Western,’ were derived from food frequency questionnaires and used to model quantitative metabolite scores via sparse partial least squares modelling of blood metabolome data. Cognitive development was assessed using the Bayley Scales of Infant Development at 2.5 years and the Wechsler Intelligence Scale for Children at age 10. Head circumference was measured from 20 weeks gestation to 10 years, and calibrated using related anthropometric measures. Growth trajectories were evaluated using linear mixed models and latent class trajectory models. Parental and child genetic influences for cognition and head circumference were controlled by including polygenic risk scores derived from genomic data. We found that a Western dietary pattern during pregnancy was associated with lower cognitive scores at age 2.5 (β −1.24 [−2.16, −0.32], p = 0.008) and reduced head circumference growth (p-interaction < 0.0001). We found that a Varied dietary pattern during pregnancy was associated with higher estimated intelligence quotient (IQ) at age 10 (β 1.29 [0.27, 2.3], p = 0.014). Additionally, head circumference growth was associated with higher cognitive scores at age 10 (β 3.40 [1.21, 5.60], p = 0.002), and it partly mediates the association between the Varied dietary pattern and estimated IQ (proportion mediated 13.5% [0.01, 0.71], p = 0.034). Extended breastfeeding duration was also independently associated with increased head circumference growth (p-interaction < 0.0001). These patterns and correlations were consistent even after adjusting for potential confounders and accounting for genetic influences. Conclusions: Our findings reveal that a Western dietary pattern during pregnancy is associated with lower cognitive scores at age 2.5 and decreased head circumference growth, suggesting potential adverse impacts on early neurodevelopment. Conversely, a Varied dietary pattern is linked with a higher estimated IQ at age 10, with head circumference growth contributing to this positive outcome. These findings highlight the critical role of maternal nutrition during pregnancy, and duration of breastfeeding, in promoting optimal neurodevelopmental outcomes. Effective public health strategies should therefore focus on enhancing maternal dietary practices to support better cognitive and physical development in children.
- 10 April 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (4) , e1004454
Open AccessMaternal dietary patterns, breastfeeding duration, and their association with child cognitive function and head circumference growth: A prospective mother–child cohort study
Background: Early life is a critical period for neurodevelopment, where factors such as maternal nutrition and breastfeeding duration significantly impact the growth of head circumference and cognitive development in children. Our study aimed to explore the associations between maternal dietary patterns during pregnancy, duration of breastfeeding, and their impacts on child head circumference and cognitive outcomes. Methods and findings: Our study utilised data from the Copenhagen Prospective Studies on Asthma in Childhood 2010 cohort, which enrolled 700 mother–child pairs between 2008 and 2010 with 86% clinical follow-up at age 10. Pregnancy dietary patterns, described as ‘Varied’ and ‘Western,’ were derived from food frequency questionnaires and used to model quantitative metabolite scores via sparse partial least squares modelling of blood metabolome data. Cognitive development was assessed using the Bayley Scales of Infant Development at 2.5 years and the Wechsler Intelligence Scale for Children at age 10. Head circumference was measured from 20 weeks gestation to 10 years, and calibrated using related anthropometric measures. Growth trajectories were evaluated using linear mixed models and latent class trajectory models. Parental and child genetic influences for cognition and head circumference were controlled by including polygenic risk scores derived from genomic data. We found that a Western dietary pattern during pregnancy was associated with lower cognitive scores at age 2.5 (β −1.24 [−2.16, −0.32], p = 0.008) and reduced head circumference growth (p-interaction < 0.0001). We found that a Varied dietary pattern during pregnancy was associated with higher estimated intelligence quotient (IQ) at age 10 (β 1.29 [0.27, 2.3], p = 0.014). Additionally, head circumference growth was associated with higher cognitive scores at age 10 (β 3.40 [1.21, 5.60], p = 0.002), and it partly mediates the association between the Varied dietary pattern and estimated IQ (proportion mediated 13.5% [0.01, 0.71], p = 0.034). Extended breastfeeding duration was also independently associated with increased head circumference growth (p-interaction < 0.0001). These patterns and correlations were consistent even after adjusting for potential confounders and accounting for genetic influences. Conclusions: Our findings reveal that a Western dietary pattern during pregnancy is associated with lower cognitive scores at age 2.5 and decreased head circumference growth, suggesting potential adverse impacts on early neurodevelopment. Conversely, a Varied dietary pattern is linked with a higher estimated IQ at age 10, with head circumference growth contributing to this positive outcome. These findings highlight the critical role of maternal nutrition during pregnancy, and duration of breastfeeding, in promoting optimal neurodevelopmental outcomes. Effective public health strategies should therefore focus on enhancing maternal dietary practices to support better cognitive and physical development in children.
- Top Cited Papers
- 3 March 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (3) , 586-601
A western dietary pattern during pregnancy is associated with neurodevelopmental disorders in childhood and adolescence
Despite the high prevalence of neurodevelopmental disorders, the influence of maternal diet during pregnancy on child neurodevelopment remains understudied. Here we show that a western dietary pattern during pregnancy is associated with child neurodevelopmental disorders. We analyse self-reported maternal dietary patterns at 24 weeks of pregnancy and clinically evaluated neurodevelopmental disorders at 10 years of age in the COPSAC2010 cohort (n = 508). We find significant associations with attention-deficit hyperactivity disorder (ADHD) and autism diagnoses. We validate the ADHD findings in three large, independent mother–child cohorts (n = 59,725, n = 656 and n = 348) through self-reported dietary modelling, maternal blood metabolomics and foetal blood metabolomics. Metabolome analyses identify 15 mediating metabolites in pregnancy that improve ADHD prediction. Longitudinal blood metabolome analyses, incorporating five time points per cohort in two independent cohorts, reveal that associations between western dietary pattern metabolite scores and neurodevelopmental outcomes are consistently significant in early–mid-pregnancy. These findings highlight the potential for targeted prenatal dietary interventions to prevent neurodevelopmental disorders and emphasise the importance of early intervention.
- 3 March 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (3) , 586-601
Top Cited PapersA western dietary pattern during pregnancy is associated with neurodevelopmental disorders in childhood and adolescence
Despite the high prevalence of neurodevelopmental disorders, the influence of maternal diet during pregnancy on child neurodevelopment remains understudied. Here we show that a western dietary pattern during pregnancy is associated with child neurodevelopmental disorders. We analyse self-reported maternal dietary patterns at 24 weeks of pregnancy and clinically evaluated neurodevelopmental disorders at 10 years of age in the COPSAC2010 cohort (n = 508). We find significant associations with attention-deficit hyperactivity disorder (ADHD) and autism diagnoses. We validate the ADHD findings in three large, independent mother–child cohorts (n = 59,725, n = 656 and n = 348) through self-reported dietary modelling, maternal blood metabolomics and foetal blood metabolomics. Metabolome analyses identify 15 mediating metabolites in pregnancy that improve ADHD prediction. Longitudinal blood metabolome analyses, incorporating five time points per cohort in two independent cohorts, reveal that associations between western dietary pattern metabolite scores and neurodevelopmental outcomes are consistently significant in early–mid-pregnancy. These findings highlight the potential for targeted prenatal dietary interventions to prevent neurodevelopmental disorders and emphasise the importance of early intervention.
- Open Access
- 30 September 2024
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 67 (1) , e64
Impact of early risk factors on schizophrenia risk and age of diagnosis: A Danish population-based register study
Background: While several risk factors for schizophrenia have been identified, their individual impacts are rather small. The relative independent and cumulative impacts of multiple risk factors on disease risk and age of onset warrant further investigation. Study design: We conducted a register-based case–control study including all individuals receiving a schizophrenia spectrum disorder in Denmark from 1973 to 2018 (N = 29,142), and a healthy control sample matched 5:1 on age, sex, and parental socioeconomic status (N = 136,387). Register data included parental history of psychiatric illness, birth weight, gestational age, season of birth, population density of birthplace, immigration, paternal age, and Apgar scores. Data were analysed using logistic regression and machine learning. Results: Parental history of psychiatric illness (OR = 2.32 [95%CI 2.21–2.43]), high paternal age (OR = 1.30 [1.16–1.45]), and low birth weight (OR = 1.28 [1.16–1.41]) increased the odds of belonging to the patient group. In contrast, being a second-generation immigrant (OR = 0.65 [0.61–0.69]) and high population density of the birthplace (OR = 0.92 [0.89–0.96]) decreased the odds. The findings were supported by a decision tree analysis where parental history, paternal age, and birth weight contributed most to diagnostic classification (ACCtest = 0.69, AUCtest = 0.59, p < 0.001). Twenty percent of patients were child-onset cases. Here, female sex (OR = 1.82 [1.69–1.97]) and parental psychiatric illness (OR = 1.62 [1.49–1.77]) increased the odds of receiving the diagnosis <18 years. Conclusion: Multiple early factors contribute independently to a higher psychosis risk, suggesting cumulative effects leading to symptom onset. Routine assessments of the most influential risk factors could be incorporated into clinical practise. Being female increased the risk of diagnosis during childhood, suggesting sex differences in the developmental trajectories of the disorder.
- 30 September 2024
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 67 (1) , e64
Open AccessImpact of early risk factors on schizophrenia risk and age of diagnosis: A Danish population-based register study
Background: While several risk factors for schizophrenia have been identified, their individual impacts are rather small. The relative independent and cumulative impacts of multiple risk factors on disease risk and age of onset warrant further investigation. Study design: We conducted a register-based case–control study including all individuals receiving a schizophrenia spectrum disorder in Denmark from 1973 to 2018 (N = 29,142), and a healthy control sample matched 5:1 on age, sex, and parental socioeconomic status (N = 136,387). Register data included parental history of psychiatric illness, birth weight, gestational age, season of birth, population density of birthplace, immigration, paternal age, and Apgar scores. Data were analysed using logistic regression and machine learning. Results: Parental history of psychiatric illness (OR = 2.32 [95%CI 2.21–2.43]), high paternal age (OR = 1.30 [1.16–1.45]), and low birth weight (OR = 1.28 [1.16–1.41]) increased the odds of belonging to the patient group. In contrast, being a second-generation immigrant (OR = 0.65 [0.61–0.69]) and high population density of the birthplace (OR = 0.92 [0.89–0.96]) decreased the odds. The findings were supported by a decision tree analysis where parental history, paternal age, and birth weight contributed most to diagnostic classification (ACCtest = 0.69, AUCtest = 0.59, p < 0.001). Twenty percent of patients were child-onset cases. Here, female sex (OR = 1.82 [1.69–1.97]) and parental psychiatric illness (OR = 1.62 [1.49–1.77]) increased the odds of receiving the diagnosis <18 years. Conclusion: Multiple early factors contribute independently to a higher psychosis risk, suggesting cumulative effects leading to symptom onset. Routine assessments of the most influential risk factors could be incorporated into clinical practise. Being female increased the risk of diagnosis during childhood, suggesting sex differences in the developmental trajectories of the disorder.